These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 14531041)

  • 1. Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice.
    Poewe W; Scherfler C
    Mov Disord; 2003 Oct; 18 Suppl 7():S16-21. PubMed ID: 14531041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
    Pirker W
    Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of dopamine transporter SPECT for the practitioner and the general neurologist.
    Oertel WH; Gerstner A; Höffken H; Dodel RC; Eggert KM; Möller JC
    Mov Disord; 2003 Oct; 18 Suppl 7():S9-15. PubMed ID: 14531040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders.
    Marshall V; Grosset DG
    Mov Disord; 2003 Oct; 18 Suppl 7():S22-7. PubMed ID: 14531042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine transporter: basic aspects and neuroimaging.
    Piccini PP
    Mov Disord; 2003 Oct; 18 Suppl 7():S3-8. PubMed ID: 14531039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DAT imaging in drug-induced and psychogenic parkinsonism.
    Tolosa E; Coelho M; Gallardo M
    Mov Disord; 2003 Oct; 18 Suppl 7():S28-33. PubMed ID: 14531043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand.
    Løkkegaard A; Werdelin LM; Friberg L
    Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1623-9. PubMed ID: 12458397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Against.
    Frey KA
    Eur J Nucl Med Mol Imaging; 2002 May; 29(5):715-7. PubMed ID: 11976814
    [No Abstract]   [Full Text] [Related]  

  • 9. [Imaging of dopamine transporter with Tc99m-Trodat-SPECT in movement disorders].
    Kanyó B; Argyelán M; Dibó G; Szakonyi Z; Vécsei L; Fülöp F; Láncz A; Forgács P; Pávics L
    Ideggyogy Sz; 2003 Jul; 56(7-8):231-40. PubMed ID: 12971118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of DAT-SPECT in the diagnostic work up of parkinsonism.
    Scherfler C; Schwarz J; Antonini A; Grosset D; Valldeoriola F; Marek K; Oertel W; Tolosa E; Lees AJ; Poewe W
    Mov Disord; 2007 Jul; 22(9):1229-38. PubMed ID: 17486648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine transporter SPECT: how to remove subjectivity?
    Scherfler C; Nocker M
    Mov Disord; 2009; 24 Suppl 2():S721-4. PubMed ID: 19877234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Radionuclide techniques in the diagnosis of parkinsonian syndromes].
    Pöpperl G; Tatsch K
    MMW Fortschr Med; 2004 Mar; 146(10):24-6. PubMed ID: 15347073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular imaging studies in Parkinson disease: reducing diagnostic uncertainty.
    Felicio AC; Shih MC; Godeiro-Junior C; Andrade LA; Bressan RA; Ferraz HB
    Neurologist; 2009 Jan; 15(1):6-16. PubMed ID: 19131852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine transporter binding study in differentiating carbon disulfide induced parkinsonism from idiopathic parkinsonism.
    Huang CC; Yen TC; Shih TS; Chang HY; Chu NS
    Neurotoxicology; 2004 Mar; 25(3):341-7. PubMed ID: 15019297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective and efficient diagnosis of parkinsonism: the role of dopamine transporter SPECT imaging with ioflupane I-123 injection (DaTscan™).
    Cummings JL; Fine MJ; Grachev ID; Jarecke CR; Johnson MK; Kuo PH; Schaecher KL; Oberdorf JA; Rezak M; Riley DE; Truong D
    Am J Manag Care; 2014 Mar; 20(5 Suppl):S97-109. PubMed ID: 24773455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of dopamine transporter single photon emission computed tomography imaging using I-123 ioflupane on diagnoses of patients with parkinsonian syndromes.
    Bairactaris C; Demakopoulos N; Tripsianis G; Sioka C; Farmakiotis D; Vadikolias K; Heliopoulos I; Georgoulias P; Tsougos I; Papanastasiou I; Piperidou C
    J Clin Neurosci; 2009 Feb; 16(2):246-52. PubMed ID: 19097795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice.
    Ba F; Martin WR
    Parkinsonism Relat Disord; 2015 Feb; 21(2):87-94. PubMed ID: 25487733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine transporter SPECT imaging in Parkinson’s disease and parkinsonian disorders.
    Akdemir ÜÖ; Bora Tokçaer A; Atay LÖ
    Turk J Med Sci; 2021 Apr; 51(2):400-410. PubMed ID: 33237660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
    Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
    Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dopaminergic neurotransmission image in Parkinsonian syndromes].
    García Solís D
    Rev Esp Med Nucl; 2005; 24(4):255-76. PubMed ID: 16122412
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.